Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A structurally derived model of subunit-dependent NMDA receptor function.

Gibb AJ, Ogden KK, McDaniel MJ, Vance KM, Kell SA, Butch C, Burger P, Liotta DC, Traynelis SF.

J Physiol. 2018 Sep;596(17):4057-4089. doi: 10.1113/JP276093. Epub 2018 Aug 1.

2.

An Atypical Case of Bartonella henselae Osteomyelitis and Hepatic Disease.

Mathews DM, Vance KM, McMahon PM, Boston C, Bolton MT.

Case Rep Pediatr. 2018 Apr 5;2018:2750275. doi: 10.1155/2018/2750275. eCollection 2018.

3.

A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.

Swanger SA, Vance KM, Acker TM, Zimmerman SS, DiRaddo JO, Myers SJ, Bundgaard C, Mosley CA, Summer SL, Menaldino DS, Jensen HS, Liotta DC, Traynelis SF.

ACS Chem Neurosci. 2018 Feb 21;9(2):306-319. doi: 10.1021/acschemneuro.7b00329. Epub 2017 Nov 2.

4.

NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus.

Swanger SA, Vance KM, Pare JF, Sotty F, Fog K, Smith Y, Traynelis SF.

J Neurosci. 2015 Dec 2;35(48):15971-83. doi: 10.1523/JNEUROSCI.1702-15.2015.

5.

PAR1-activated astrocytes in the nucleus of the solitary tract stimulate adjacent neurons via NMDA receptors.

Vance KM, Rogers RC, Hermann GE.

J Neurosci. 2015 Jan 14;35(2):776-85. doi: 10.1523/JNEUROSCI.3105-14.2015.

6.

NMDA receptors control vagal afferent excitability in the nucleus of the solitary tract.

Vance KM, Rogers RC, Hermann GE.

Brain Res. 2015 Jan 21;1595:84-91. doi: 10.1016/j.brainres.2014.11.010. Epub 2014 Nov 15.

7.

Artemisia santolinifolia enhances glutamatergic neurotransmission in the nucleus of the solitary tract.

Vance KM, Ribnicky DM, Rogers RC, Hermann GE.

Neurosci Lett. 2014 Oct 17;582:115-9. doi: 10.1016/j.neulet.2014.08.048. Epub 2014 Sep 9.

8.

St. John's Wort enhances the synaptic activity of the nucleus of the solitary tract.

Vance KM, Ribnicky DM, Hermann GE, Rogers RC.

Nutrition. 2014 Jul-Aug;30(7-8 Suppl):S37-42. doi: 10.1016/j.nut.2014.02.008. Epub 2014 Feb 28.

9.

Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.

Acker TM, Khatri A, Vance KM, Slabber C, Bacsa J, Snyder JP, Traynelis SF, Liotta DC.

J Med Chem. 2013 Aug 22;56(16):6434-56. doi: 10.1021/jm400652r. Epub 2013 Aug 2.

10.

Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors.

Hansen KB, Tajima N, Risgaard R, Perszyk RE, Jørgensen L, Vance KM, Ogden KK, Clausen RP, Furukawa H, Traynelis SF.

Mol Pharmacol. 2013 Jul;84(1):114-27. doi: 10.1124/mol.113.085803. Epub 2013 Apr 26.

11.

Modal gating of GluN1/GluN2D NMDA receptors.

Vance KM, Hansen KB, Traynelis SF.

Neuropharmacology. 2013 Aug;71:184-90. doi: 10.1016/j.neuropharm.2013.03.018. Epub 2013 Apr 8.

12.

GluN1 splice variant control of GluN1/GluN2D NMDA receptors.

Vance KM, Hansen KB, Traynelis SF.

J Physiol. 2012 Aug 15;590(16):3857-75. doi: 10.1113/jphysiol.2012.234062. Epub 2012 May 28.

13.

Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators.

Acker TM, Yuan H, Hansen KB, Vance KM, Ogden KK, Jensen HS, Burger PB, Mullasseril P, Snyder JP, Liotta DC, Traynelis SF.

Mol Pharmacol. 2011 Nov;80(5):782-95. doi: 10.1124/mol.111.073239. Epub 2011 Aug 1.

14.

Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors.

Vance KM, Simorowski N, Traynelis SF, Furukawa H.

Nat Commun. 2011;2:294. doi: 10.1038/ncomms1295.

15.

A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors.

Mullasseril P, Hansen KB, Vance KM, Ogden KK, Yuan H, Kurtkaya NL, Santangelo R, Orr AG, Le P, Vellano KM, Liotta DC, Traynelis SF.

Nat Commun. 2010 Oct 5;1:90. doi: 10.1038/ncomms1085.

16.

Glutamate receptor ion channels: structure, regulation, and function.

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R.

Pharmacol Rev. 2010 Sep;62(3):405-96. doi: 10.1124/pr.109.002451. Review. Erratum in: Pharmacol Rev. 2014 Oct;66(4):1141.

17.

Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.

Hansen KB, Mullasseril P, Dawit S, Kurtkaya NL, Yuan H, Vance KM, Orr AG, Kvist T, Ogden KK, Le P, Vellano KM, Lewis I, Kurtkaya S, Du Y, Qui M, Murphy TJ, Snyder JP, Bräuner-Osborne H, Traynelis SF.

J Pharmacol Exp Ther. 2010 Jun;333(3):650-62. doi: 10.1124/jpet.110.166256. Epub 2010 Mar 2.

18.

Control of NMDA receptor function by the NR2 subunit amino-terminal domain.

Yuan H, Hansen KB, Vance KM, Ogden KK, Traynelis SF.

J Neurosci. 2009 Sep 30;29(39):12045-58. doi: 10.1523/JNEUROSCI.1365-09.2009.

19.

The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors.

Yuan H, Vance KM, Junge CE, Geballe MT, Snyder JP, Hepler JR, Yepes M, Low CM, Traynelis SF.

J Biol Chem. 2009 May 8;284(19):12862-73. doi: 10.1074/jbc.M805123200. Epub 2009 Feb 24.

20.

Alk3/Bmpr1a receptor is required for development of the atrioventricular canal into valves and annulus fibrosus.

Gaussin V, Morley GE, Cox L, Zwijsen A, Vance KM, Emile L, Tian Y, Liu J, Hong C, Myers D, Conway SJ, Depre C, Mishina Y, Behringer RR, Hanks MC, Schneider MD, Huylebroeck D, Fishman GI, Burch JB, Vatner SF.

Circ Res. 2005 Aug 5;97(3):219-26. Epub 2005 Jul 21.

Supplemental Content

Loading ...
Support Center